Loading
TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer and 5 more.
Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Gemcitabine. IntOGen calls it a driver in 7 cohorts (5 activating, 2 loss-of-function), covering Adrenocortical Carcinoma, Acute Myeloid Leukaemia, Bladder/Urinary Tract, Lung Squamous Cell Carcinoma, Malignant Lymphoma, Neuroblastoma and others.
In plain words · TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer and 5 more.
TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer and 5 more.
Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration.
No product in this corpus aims at TNC yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA TNC: RNA tissue enhanced (blood vessel 346 nTPM, smooth muscle 447 nTPM); no normal tissue stained high. Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer, Lymphoma, Ovarian cancer, Leukaemia, Lung cancer (all types) and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P24821; CIViC gene TNC; IntOGen TNC; Human Protein Atlas TNC tissue; Open Targets ENSG00000041982 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Gulcher J.R. et al, Proc. Natl. Acad. Sci. U.S.A, 1989, "An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites". Source.
Sources: HGNC HGNC:5318 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P24821 (protein name, function text, keywords and locations (REST API)); CIViC gene TNC (2 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Cancer (GraphQL API, CC0)); IntOGen TNC (driver in 7 cohorts (Act 5, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6. In tumours, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells. Location: Secreted, extracellular space, extracellular matrix (UniProt). Locus 9q33.1 (HGNC).
RNA: tissue enhanced (blood vessel 346 nTPM, smooth muscle 447 nTPM), detected in all normal tissues.
No normal tissue stained high.
No cancer stained high; medium in breast cancer, cervical cancer, endometrial cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TNC" OR ABSTRACT:"TNC" OR TITLE:"tenascin C" OR ABSTRACT:"tenascin C" OR TITLE:"Tenascin" OR ABSTRACT:"Tenascin" OR TITLE:"MGC167029" OR ABSTRACT:"MGC167029" OR TITLE:"DFNA56" OR ABSTRACT:"DFNA56") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TNC, not a curated reading list.
Shares Neuroblastoma (paediatric), CIViC, IntOGen, Pancreatic ductal adenocarcinoma.
Shares Neuroblastoma (paediatric), Bladder & urothelial cancer, IntOGen, Pancreatic ductal adenocarcinoma.
Shares Neuroblastoma (paediatric), Acute myeloid leukaemia, IntOGen, Pancreatic ductal adenocarcinoma.
Shares Adrenocortical carcinoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Adrenocortical carcinoma, CIViC, IntOGen, Ovarian cancer.
Shares Adrenocortical carcinoma, IntOGen.
Shares Adrenocortical carcinoma, CIViC, IntOGen.
Shares Neuroblastoma (paediatric), CIViC.